axsome therapeutics - AXSM
AXSM
Close Chg Chg %
98.19 0.49 0.50%
Closed Market
98.68
+0.49 (0.50%)
Volume: 427.25K
Last Updated:
Nov 22, 2024, 4:00 PM EDT
Company Overview: axsome therapeutics - AXSM
AXSM Key Data
| Open $98.99 | Day Range 96.79 - 99.30 |
| 52 Week Range 60.28 - 104.98 | Market Cap $4.76B |
| Shares Outstanding 48.46M | Public Float 39.56M |
| Beta 1.25 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$6.54 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 534.22K |
AXSM Performance
| 1 Week | 5.91% | ||
| 1 Month | 9.80% | ||
| 3 Months | 12.15% | ||
| 1 Year | 57.76% | ||
| 5 Years | 193.52% |
AXSM Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
17
Full Ratings ➔
About axsome therapeutics - AXSM
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
AXSM At a Glance
Axsome Therapeutics, Inc.
One World Trade Center
New York, New York 10007
| Phone | 1-212-332-3241 | Revenue | 270.60M | |
| Industry | Biotechnology | Net Income | -239,238,000.00 | |
| Sector | Health Technology | 2023 Sales Growth | 440.799% | |
| Fiscal Year-end | 12 / 2024 | Employees | 545 | |
| View SEC Filings |
AXSM Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 13.361 |
| Price to Book Ratio | 19.734 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -19.399 |
| Enterprise Value to Sales | 12.622 |
| Total Debt to Enterprise Value | 0.055 |
AXSM Efficiency
| Revenue/Employee | 496,513.761 |
| Income Per Employee | -438,968.807 |
| Receivables Turnover | 2.854 |
| Total Asset Turnover | 0.588 |
AXSM Liquidity
| Current Ratio | 3.632 |
| Quick Ratio | 3.523 |
| Cash Ratio | 2.781 |
AXSM Profitability
| Gross Margin | 87.842 |
| Operating Margin | -67.593 |
| Pretax Margin | -88.055 |
| Net Margin | -88.41 |
| Return on Assets | -52.025 |
| Return on Equity | -159.209 |
| Return on Total Capital | -63.40 |
| Return on Invested Capital | -82.51 |
AXSM Capital Structure
| Total Debt to Total Equity | 97.589 |
| Total Debt to Total Capital | 49.39 |
| Total Debt to Total Assets | 31.683 |
| Long-Term Debt to Equity | 96.925 |
| Long-Term Debt to Total Capital | 49.054 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Axsome Therapeutics - AXSM
Collapse All in section
| All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| - | - | 50.04M | 270.60M | - |
Sales Growth
| - | - | - | +440.80% | - |
Cost of Goods Sold (COGS) incl D&A
| 77.72K | 1.16M | 10.76M | 32.90M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 77.72K | 1.16M | 5.56M | 6.83M | |
Depreciation
| 77.72K | 1.16M | 1.42M | 459.00K | |
Amortization of Intangibles
| - | - | 4.14M | 6.38M | - |
COGS Growth
| +108.19% | +1,387.00% | +831.22% | +205.70% | |
Gross Income
| (77.72K) | (1.16M) | 39.28M | 237.70M | |
Gross Income Growth
| -108.19% | -1,387.00% | +3,498.51% | +505.22% | |
Gross Profit Margin
| - | - | +78.49% | +87.84% | - |
| 2020 | 2021 | 2022 | 2023 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 99.06M | 123.55M | 215.28M | 420.61M | |
Research & Development
| 70.17M | 57.98M | 57.68M | 97.48M | |
Other SG&A
| 28.90M | 65.57M | 157.59M | 323.12M | |
SGA Growth
| +47.40% | +24.72% | +74.24% | +95.38% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | 1.25M | 3.80M | 48.92M | |
EBIT after Unusual Expense
| (100.39M) | (124.71M) | (179.80M) | (231.83M) | |
Non Operating Income/Expense
| - | - | - | - | - |
Non-Operating Interest Income
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 2.57M | 5.70M | 7.33M | 6.45M | |
Interest Expense Growth
| +107.00% | +122.00% | +28.77% | -12.02% | |
Gross Interest Expense
| 2.57M | 5.70M | 7.33M | 6.45M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (102.95M) | (130.40M) | (187.13M) | (238.28M) | |
Pretax Income Growth
| -50.33% | -26.66% | -43.50% | -27.33% | |
Pretax Margin
| - | - | -373.99% | -88.06% | - |
Income Tax
| - | - | (53.58K) | 960.00K | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | 53.58K | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (102.90M) | (130.40M) | (187.13M) | (239.24M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (102.90M) | (130.40M) | (187.13M) | (239.24M) | |
Net Income Growth
| -50.56% | -26.73% | -43.50% | -27.84% | |
Net Margin Growth
| - | - | -373.99% | -88.41% | - |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (102.90M) | (130.40M) | (187.13M) | (239.24M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (102.90M) | (130.40M) | (187.13M) | (239.24M) | |
EPS (Basic)
| -2.7656 | -3.4664 | -4.6029 | -5.2666 | |
EPS (Basic) Growth
| -37.66% | -25.34% | -32.79% | -14.42% | |
Basic Shares Outstanding
| 37.21M | 37.62M | 40.66M | 45.43M | |
EPS (Diluted)
| -2.7656 | -3.4664 | -4.6029 | -5.2666 | |
EPS (Diluted) Growth
| -37.66% | -25.34% | -32.79% | -14.42% | |
Diluted Shares Outstanding
| 37.21M | 37.62M | 40.66M | 45.43M | |
EBITDA
| (99.06M) | (123.55M) | (170.44M) | (176.07M) | |
EBITDA Growth
| -47.40% | -24.72% | -37.95% | -3.31% | |
EBITDA Margin
| - | - | -340.62% | -65.07% | - |
Snapshot
| Average Recommendation | BUY | Average Target Price | 128.824 | |
| Number of Ratings | 17 | Current Quarters Estimate | -0.986 | |
| FY Report Date | 12 / 2024 | Current Year's Estimate | -5.479 | |
| Last Quarter’s Earnings | -1.34 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -5.27 | Next Fiscal Year Estimate | -1.443 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 17 | 10 | 16 | 17 |
| Mean Estimate | -0.99 | -0.94 | -5.48 | -1.44 |
| High Estimates | -0.46 | -0.48 | -4.90 | 2.99 |
| Low Estimate | -1.37 | -1.40 | -6.04 | -4.12 |
| Coefficient of Variance | -27.70 | -31.19 | -6.59 | -132.08 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 16 | 16 | 16 |
| OVERWEIGHT | 1 | 1 | 1 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Axsome Therapeutics - AXSM
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Axsome Therapeutics - AXSM
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jun 12, 2024 | Susan Mahony Director | 5,799 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 12, 2024 | Roger A. Jeffs Director | 5,799 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 12, 2024 | Mark Herbert Coleman Director | 5,799 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 12, 2024 | Mark E. Saad Director | 5,799 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 30, 2024 | Mark Herbert Coleman Director | 14,600 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $75.14 per share | 1,097,044.00 |
| May 30, 2024 | Mark L. Jacobson Chief Operating Officer | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 30, 2024 | Mark L. Jacobson Chief Operating Officer | 5,783 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $74.31 per share | 429,734.73 |
| May 30, 2024 | Mark L. Jacobson Chief Operating Officer | 13,693 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $1.3 per share | 17,800.90 |
| Mar 18, 2024 | Roger A. Jeffs Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 18, 2024 | Roger A. Jeffs Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 18, 2024 | Roger A. Jeffs Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 18, 2024 | Roger A. Jeffs Director | 120,756 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $71.61 per share | 8,647,337.16 |
| Mar 18, 2024 | Roger A. Jeffs Director | 123,103 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $29.91 per share | 3,682,010.73 |
| Mar 18, 2024 | Roger A. Jeffs Director | 120,756 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $69.7 per share | 8,416,693.20 |
| Mar 18, 2024 | Roger A. Jeffs Director | 137,732 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $25.53 per share | 3,516,297.96 |
| Mar 18, 2024 | Roger A. Jeffs Director | 120,756 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $69.7 per share | 8,416,693.20 |
| Mar 1, 2024 | Herriott Tabuteau CHIEF EXECUTIVE OFFICER; Director | 87,192 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 1, 2024 | Herriott Tabuteau CHIEF EXECUTIVE OFFICER; Director | 47,886 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 1, 2024 | Nick Pizzie CHIEF FINANCIAL OFFICER | 28,722 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 1, 2024 | Nick Pizzie CHIEF FINANCIAL OFFICER | 15,774 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |